FDA advisory panel reviews Moderna's mRNA flu vaccine for older adults.
An FDA advisory committee is meeting to evaluate Moderna's mFlusiva, an mRNA-based flu vaccine candidate for people 50 and older. A study of 40,000 people showed the vaccine reduced flu cases by about 27% compared to a standard-dose vaccine. The meeting follows a public dispute earlier in 2026 when an FDA official initially blocked the application, citing concerns about the comparator vaccine used in the main study.
3
Divergence score
2 outlets covered it, splitting into 2 framing camps across 2 bias groups.
2 camps
2 bias groups
Market signalBETA
The spectrum · how 2 outlets placed this story
LeftCenterRight
Washington Times
Reuters
Supportive of action
Neutral
Dismissive
Critical
Alarmist
International angle
The split, in one line
The Washington Times details the internal FDA dispute and Kennedy-era scrutiny; Reuters leads with the regulators reversed course framing before the cut.
How each outlet covered it
Lightly covered so far
Too few outlets to map a left-right split. Here is each take as it stands.
Sparse coverage · 2 outlets
“Moderna's mRNA flu vaccine faces FDA advisory panel scrutiny”
“FDA panel considers a first-of-its-kind flu vaccine using mRNA technology”
Tracked claims from across the political spectrum
Fact ledger
Corroborated
Disputed